echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Immunity: Studies have found multiple developmental pathways for pulmonary macrophages, which may explain why immune cells exacerbate lung disease

    Immunity: Studies have found multiple developmental pathways for pulmonary macrophages, which may explain why immune cells exacerbate lung disease

    • Last Update: 2021-01-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In some cases, immune cells in the lungs can aggravate viral attacks.
    a recent study, researchers at sweden's Karolinska Institute described the development of macrophage lungs and shed light on which cells may be behind severe lung disease.
    study, which could help treat diseases such as COVID-19 in the future, was published recently in the journal Immunity.
    DOI:10.1016/j.immuni.2020.12.003 Macrophages are immune cells that protect the lungs from viruses and bacteria.
    , in some cases, pulmonary macrophages can also cause serious lung diseases such as chronic obstructive pulmonary disease (COPD) and COVID-19.
    study, researchers used models to study the development of macrophages in the lungs.
    combined the model with RNA sequencing to discover the process by which single-nucleocytes in the blood become lung macrophages.
    study, "ScRNA-seq Experimental Emoticons", we found that typical monocytes can migrate to the gas channel and lung tissue and convert them into macrophages to protect lung health and function.
    same time, we also found a special single-nucleocyte, HLA-DRhi, which is an intermediate immune cell between a blood monocyte and a macrophage in the vagina.
    These HLA-DRhi mononucleocytes can leave the blood circulation and migrate to lung tissue," said Timmwillinger, an associate professor in the Hardinger Department of Medicine at the Karolinska Institute, who led the study.
    Four weeks after the transplantation of CD34 plus cells, the presence of extravascular CD14 plus HLA-DRhi monocyte populations in the lungs, rather than typical monocytes, does not migrate to lung tissue after developing into macrophages in the pulmonary blood vessels.
    macrophages that form macrophage pathways in the lungs may be associated with some serious lung diseases.
    in respiratory infections, monocytes in the lungs develop into macrophages that fight viruses and bacteria.
    but certain types of macrophages can also cause severe inflammation and infection," said Elza Evren, lead author of the study and a doctoral student with the Tim Willinger team.
    researchers believe that in the new coronavirus SARS-COV-2 infection, protective, anti-inflammatory macrophages will be replaced by blood monocytes converted into inflammatory pulmonary macrophages.
    "s studies have shown that these macrophages from blood monocytes are associated with the severity of the human condition in COVID-19 and the extent of damage to the lungs.
    patients with severe COVID-19 have fewer HLA-DRhi monocytes in their blood, possibly because they leave the blood and enter the lungs.
    our results suggest that future treatments should focus on inflammatory macrophages and monocytes to reduce lung damage and mortality from severe COVID-19.
    ," Tim Willinger said.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.